Evotec receives first milestones in TargetAD collaboration
Evotec AG announced the successful achievement of the first milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen") for the identification and selection of three selected targets from the TargetADdatabase.
These target selections were achieved under the agreement between Evotec and Janssen, facilitated by the Johnson & Johnson Innovation Center in California, signed in November 2013. Under the terms of the agreement, Janssen and Evotec are collaborating to identify new drug targets for discovery of novel treatment approaches to Alzheimer's disease ('AD').
Janssen has the option to internalize selected targets and therapeutic candidates and progress them into pre-clinical and clinical development. Janssen funds target drug discovery research via a combination of defined research payments and progress-related milestones.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are delighted to see the first validation of our collaboration with Janssen. The joint project team has been very productive and we are looking forward to leveraging our innovative Alzheimer's disease approaches during the years to come."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Valuable raw materials from olive waste - ETH spin-off Gaia Tech transforms waste from olive oil production into high-quality antioxidants for use in cosmetics or food

A sugar analysis could reveal different types of cancer - In the future, a little saliva may be enough to detect an incipient cancer
Deuterium Depletion: A New Concept in Anticancer Drug Development
Category:Chemotherapeutic_agents
Febit Receives European Patent for Gene Extraction Procedure

Curcumin activates tumor suppressive signaling pathway - Researchers have identified a signaling pathway via which curcumin can suppress the metastasis of colorectal cancer cells
ORYX Successfully Completes Phase I/IIa Trial to Treat HPV-Associated Cancers

Taking antibiotics back in time - “Recreating such an ancient molecule was exhilarating, akin to bringing dinosaurs or wooly mammoths back to life”
Pharming and Swedish Orphan announce publication of randomized clinical trial results with recombinant human C1 inhibitor
Nano shake-up - UD researchers demonstrate that processing can affect size of nanocarriers for targeted drug delivery
